Table 2.
Disease Model | Animal | Format | Mitochondrial Source | Methods | Effect | Ref |
---|---|---|---|---|---|---|
Ischemia/reperfusion (I/R) | ||||||
Myocardial ischemia | NZW rabbitsa) | Mitochondria | Left ventricular | Local injection | ↑: Postischemic recovery; ↓: Infarct size | 47 |
Myocardial ischemia | NZW rabbits | Mitochondria | Pectoralis major muscle | Local injection | ↑: Postinfarct cardiac function, angiogenesis, immunomodulation; | 372 |
↓: Myocardial necrosis, apoptosis, and infarction size | ||||||
Hepatic ischemia | Wistar rats | Mitochondria | Rat liver | Splenic injection | ↓: Tissue insults, oxidative stress, cell death | 375 |
MCAOb) | Sprague–Dawley rat | Mitochondria | BHK-21 cell | IC & IA injectionc) | ↑: Functional recovery of motor activities, neuron survival; ↓: Brain lesion | 376 |
Stroke | C57BL/6 J mice | Mitochondria | Astrocyte | Direct injection | ↑: Cell-survival-related signals, plasticity | 43 |
MCAO | Sprague–Dawley rat | Mitochondria | Autologous muscle | ICVd) injection | ↑: Neurogenesis; ↓: Brain infarct volume, oxidative stress, and cell death | 448 |
Warm ischemia | Zucker diabetic fatty rat | Mitochondria | Skeletal muscle | ICAe) infusion | ↑: Mitochondrial function; ↓: Infarct size, oedema | 449 |
Heart transplantation | C57BL/6 J mice | Mitochondria | Gastrocnemius muscle | ICA infusion | ↑: Cold ischemic time; ↓: Graft tissue injury, neutrophil infiltration | 374 |
Myocardial ischemia | Yorkshire swine | Mitochondria | Pectoralis major muscle | ICA infusion | ↑: Coronary blood flow, myocardial function, perfusion; ↓: Infarct size | 450 |
Acute limb ischemia | C57BL/6 J mice | Mitochondria | muscle | Direct injection | ↑: Hindlimb function, inflammation; ↓: Infarct size, apoptosis | 377 |
Myocardial ischemia | CD1 mice | EVs | iCMs | Direct injection | ↑: Mitochondrial biogenesis; ↓: Cardiac remodeling | 390 |
Renal I/R injury | C57BL/6 mice | mtDNA, TFAM mRNA, proteins | Mouse MSC | IVf) injection | ↓: Renal lesion, inflammation | 451 |
Hepatic ischemia | C57BL/6 mice | Mitochondria | hUC-MSC-EVs | IV injection | ↓: Hepatocyte apoptosis, proinflammatory cytokines, NETg) formation | 452 |
Neurodegenerative disorders and aging | ||||||
Parkinson’s disease | Sprague–Dawley rat | Mitochondria, P-mitoh) | PC12, human osteosarcoma | Local injection | ↓: Deterioration of dopaminergic neurons, movement disorders | 379 |
Parkinson’s disease | C57BL/6 J mice | Mitochondria | HepG2 cell | IV injection | ↑: Behavioral symptoms, biochemical assay results | 380 |
Parkinson’s disease | Sprague–Dawley rat | Mitochondria, P-mito | Allogeneic liver | INi) infusion | ↑: Rotational and locomotor behavior; ↓: Mitochondrial oxidative damage | 393 |
Alzheimer’s disease | C57BL/6 mice | Mitochondria | HeLa cell | ICV injection | ↑: Cognitive performance; ↓: Gliosis, neuron loss | 394 |
Alzheimer’s disease | NMRI mice | Mitochondria | Allogeneic brain | IN infusion | ↑: Spatial memory with Alzheimer’s type degeneration | 395 |
Aging | BABL/c mice | Mitochondria | Mice liver | IV injection | ↑: Learning and memory ability, muscle function, immune responses | 396 |
Aging | Wistar rats | Mitochondria | Rat brain | ICV injection | ↑: Mitochondrial function; ↓: Depression like behaviors | 397 |
Psychiatric disorders | ||||||
MDDj) | ICR mice | Mitochondria | Hippocampus | IV injection | ↑: Antidepressant-like activity; ↓: Neuroinflammation | 381 |
Cognitive deficits | C57BL/6 J mice | Mitochondria | Human MSC | IN infusion | ↓: White matter and synaptic loss, synaptosomal mitochondrial deficiencies | 400 |
Hepatic non-ischemic disorders | ||||||
NAFLD | C57BL/6 J mice | Mitochondria | HepG2 cells | IV injection | ↑: Redox balance; ↓: Lipid content | 405 |
Liver injury | C57BL/6 J mice | Mitochondria | HepG2 cells | IV injection | ↑: Hepatic function; ↓: Decreased hepatotoxicity | 408 |
NASH | C57BL/6 J mice | microRNA | Human liver | IV injection | ↓: High Fat Diet-Induced Cirrhosis, insulin resistance, fibrosis | 429 |
Liver injury | Kunming mice | Mitochondria | Allogeneic liver | IV injection | ↑: Stress resistance, proteostasis; ↓: Oxidation, fibrosis | 407 |
Lung non-ischemic disorders | ||||||
Acute lung injury | C57BL/6 J mice | MSC | Mouse BMSCs | IN infusion | ↑: Mouse survival time; ↓: Leukocytosis, albumin leakage | 413 |
ARDS | Sprague–Dawley rat | Melatonin–mitochondria | Allogeneic liver | IV injection | ↑: Respiratory and circulatory functions; ↓: Oxidative stress, apoptosis | 385 |
Silicosis | C57BL/6 J mice | microRNA | Human MSC | IV injection | ↑: Bioenergetics; ↓: Monocyte infiltration, inflammation, fibrosis | 41 |
COPD | Sprague–Dawley rat | Mitochondria | Airway epithelium | ITk) instillation | ↓: Airway hyperresponsiveness to acetylcholine, inflammation | 416 |
ARDS | C57BL/6 mice | Mitochondria | Human MSC | IN infusion | ↑: Microbial clearance, phagocytosis of alveolar macrophages | 417 |
Acute lung injury | C57BL/6 mice | EVs | Human MSC | IN infusion | ↓: Inflammatory cell recruitment, lung injury | 418 |
Asthma | BALB/c mice | Mitochondria | iPSC-MSCl) | IT instillation | ↑: Mitochondrial function; ↓: Asthma inflammation | 415 |
Acute lung injury | C57BL/6 mice | mtDNA and proteins | Human adipose MSC | IV injection | ↑: Macrophage mitochondrial function; ↓: Lung inflammation and injury | 384 |
Central nerve injuries | ||||||
Spinal cord injury | Sprague–Dawley rat | Mitochondria | BHK Cells | Local injection | ↑: Rat neurobehaviors, nerve electrophysiology, muscle activities; | 420 |
↓: Oxidative stress and the secondary inflammatory response | ||||||
Spinal cord injury | Sprague–Dawley rat | Mitochondria | bilateral soleus muscles | Local injection | ↑: Sensory and locomotor functions; | 421 |
↓: Demyelination, oxidative stress, mitochondrial fragmentation, apoptosis | ||||||
Spinal cord injury | Sprague–Dawley rat | Mitochondria | Rat BMSCs | Direct injection | ↑: Locomotor function recovery | 422 |
Spinal cord injury | C57BL/6 mice | P-mito | BMDMsm) | IV injection | ↑: Lower limb motor function, nerve innervation, macrophage repair; | 423 |
↓: mitochondrial dysfunction and proinflammatory profile of macrophage | ||||||
Other diseases | ||||||
Multiple sclerosis | C57BL/6 mice | EVs | Neuro stem cell | ICV injection | ↓: Auxotrophy, neuroinflammation | 425 |
Tendinopathy | Sprague–Dawley rat | Mitochondria | L6 rat myoblast cell | Local injection | ↓: Inflammation, apoptosis | 426 |
Wound and muscle dystrophy | C57BL/6, sgcanull mice | Mitochondria | Human platelet | Direct injection | ↑: Pro-angiogenic function, myogenesis | 424 |
Osteoarthritis | Male Wistar rats | Mitochondria | L6 rat myoblast cell | Direct injection | ↑: Bone surface, bone volume; ↓: Joint destruction, autophagy | 427 |
a)NZW New Zealand White
b)MCAO middle cerebral artery occlusion
c)IA intra-artery; IC Intracerebral
d)ICV intracerebroventricular
e)ICA intracoronary artery
f)IV intravenous
g)NET neutrophil extracellular traps
h)P-mito Peptide-mediated mitochondria
i)IN intranasal
j)MDD Major depressive disorder
k)IT intratracheal instillation
l)iPSCs induced-pluripotent stem cells
m)BMDMs bone marrow-derived macrophages